Insulin: Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Insulin is a peptide hormone produced by the beta cells of the pancreatic islets. It is the master regulator of glucose homeostasis, facilitating cellular glucose uptake, promoting glycogen synthesis in liver and muscle, inhibiting gluconeogenesis, and regulating lipid and protein metabolism. Measuring insulin in blood provides a direct window into pancreatic beta cell function and peripheral insulin sensitivity.

The insulin assay is used clinically for several distinct purposes:

· Distinguishing diabetes subtypes: Differentiating type 1 diabetes (absolute insulin deficiency) from type 2 diabetes (relative deficiency with insulin resistance).

· Evaluating hypoglycaemia: Determining whether low blood glucose is due to endogenous insulin overproduction (insulinoma, sulfonylureas) or exogenous insulin administration.

· Quantifying insulin resistance: In research and specialised clinical settings (e.g., polycystic ovary syndrome, metabolic syndrome) using indices like HOMA‑IR.

· Assessing beta cell reserve: In established diabetes to guide treatment intensity.

Because insulin secretion is pulsatile and varies widely with nutrient intake, interpretation always requires simultaneous glucose measurement and knowledge of the clinical context.

---

2. What does it measure

a. Units of measurement

· Conventional: Microunits per millilitre (µIU/mL)

· SI units: Picomoles per litre (pmol/L)

· Conversion: 1 µIU/mL ≈ 6.945 pmol/L (often simplified as 1 µIU/mL = 6.0 pmol/L in some sources; exact factor is 6.945)

b. Normal range

Reference intervals are assay‑dependent and population‑specific. The following are representative for fasting samples:

· Fasting insulin (euglycaemic): 2 – 25 µIU/mL (14 – 174 pmol/L). Many optimal health targets suggest 2 – 10 µIU/mL for low insulin resistance.

· Postprandial (1–2 hours after meal): Up to 30–60 µIU/mL, depending on carbohydrate load.

· During oral glucose tolerance test (OGTT): Peak at 30–60 minutes, typically <150 µIU/mL.

Critical interpretive principle: Insulin levels must always be interpreted with concurrent glucose. A high insulin with normal glucose suggests insulin resistance; a high insulin with low glucose suggests pathological endogenous secretion (insulinoma, sulfonylureas); a low insulin with high glucose indicates insulin deficiency.

---

3. Other factors connected to this

a. Direct correlation (factors that increase insulin)

· Physiological:

· Postprandial state

· Pregnancy (due to placental hormones causing insulin resistance)

· Pathological:

· Insulin resistance – obesity, metabolic syndrome, type 2 diabetes (early stage), PCOS

· Insulinoma – autonomous insulin secretion despite hypoglycaemia

· Factitious hypoglycaemia due to sulfonylureas or glinides

· Acromegaly, Cushing's syndrome (counter‑regulatory hormone excess causing compensatory hyperinsulinaemia)

· Lipodystrophy syndromes

· Other:

· Certain medications – sulfonylureas, repaglinide, nateglinide, corticosteroids, some antipsychotics

b. Indirect correlation (factors that decrease insulin)

· Physiological:

· Fasting state

· Prolonged exercise

· Pathological:

· Type 1 diabetes mellitus (autoimmune beta cell destruction)

· Long‑standing type 2 diabetes with beta cell exhaustion

· Pancreatitis (acute or chronic)

· Pancreatectomy

· Cystic fibrosis – related diabetes

· Factitious hypoglycaemia due to exogenous insulin (low C‑peptide, high insulin)

· Other:

· Beta cell toxins (streptozocin, certain chemotherapies)

· Immunosuppressive drugs (tacrolimus, cyclosporine) – impair insulin secretion

c. Important methodological considerations

· Haemolysis: Can falsely lower insulin levels (interference with immunoassay).

· Sample timing: Random insulin without glucose is uninterpretable.

· Insulin antibodies: Present in some insulin‑treated patients or rarely autoimmune hypoglycaemia (Hirata disease); may interfere with assay.

· Proinsulin cross‑reactivity: Some assays cross‑react with proinsulin; important in insulinoma where proinsulin may be disproportionately elevated.

· Assay variability: Different commercial assays may yield different absolute values; serial monitoring should use the same laboratory.

---

4. Disorders related to abnormal values

a. When elevated (with corresponding glucose context)

1. Insulin resistance syndromes (normoglycaemia or hyperglycaemia):

· Metabolic syndrome, obesity, PCOS: Fasting insulin elevated, glucose normal or impaired; HOMA‑IR >2.5 indicates significant resistance.

· Acanthosis nigricans: Cutaneous marker of severe insulin resistance.

2. Type 2 diabetes (early stage):

· Fasting or postprandial hyperglycaemia with elevated insulin (compensatory hyperinsulinaemia). As beta cell failure progresses, insulin declines.

3. Insulinoma (hypoglycaemia):

· Fasting glucose <55 mg/dL with inappropriately elevated insulin (>3 µIU/mL).

· C‑peptide also elevated; sulfonylurea screen negative.

· Diagnosis confirmed by 72‑hour fast.

4. Postprandial (reactive) hypoglycaemia:

· 2–4 hours after meals, glucose low, insulin inappropriately high.

· Seen in early type 2 diabetes, gastric surgery, or idiopathic.

5. Congenital hyperinsulinism:

· Genetic disorders affecting insulin secretion; presents in infancy.

b. When low (with corresponding glucose context)

1. Type 1 diabetes:

· Fasting glucose elevated, insulin low or undetectable.

· C‑peptide low (<0.2 ng/mL).

· Autoantibodies (GAD, IA‑2, islet cell) usually positive.

2. Long‑standing type 2 diabetes:

· Progressive beta cell failure leads to declining insulin levels; patients become insulin‑requiring.

3. Pancreatogenic diabetes (Type 3c):

· Chronic pancreatitis, pancreatic cancer, haemochromatosis, cystic fibrosis.

· Insulin low despite hyperglycaemia; often associated with exocrine insufficiency.

4. Factitious hypoglycaemia from exogenous insulin:

· High insulin, low C‑peptide, low glucose.

· Seen in diabetic patients (overtreatment) or surreptitious use.

5. Hypoglycaemia due to other causes:

· Insulin‑like growth factor‑2 (IGF‑2) secreting tumours (non‑islet cell tumour hypoglycaemia) – insulin low, IGF‑2 high.

---

5. Best way to address aberrant levels

Critical principle: Insulin is a marker, not a target. Treatment aims at the underlying disorder – improving insulin sensitivity, replacing deficient insulin, or removing an autonomous source. All medical management must be supervised by a qualified physician.

a. Quick ways or using Medications (Medical Management)

Insulin resistance / type 2 diabetes (early):

· Metformin: First‑line for type 2 diabetes and insulin resistance syndromes. Reduces hepatic glucose output, improves peripheral insulin sensitivity. May lower fasting insulin over months.

· Thiazolidinediones (pioglitazone): Potent insulin sensitizers; increase subcutaneous fat storage and reduce insulin resistance. Use restricted due to adverse effects (fluid retention, fractures, bladder cancer concerns).

· GLP‑1 receptor agonists (liraglutide, semaglutide): Enhance glucose‑dependent insulin secretion, promote weight loss, improve insulin sensitivity, and preserve beta cell function.

· SGLT2 inhibitors (empagliflozin, dapagliflozin): Reduce hyperglycaemia independent of insulin; promote glycosuria and weight loss, indirectly reducing insulin demand.

· Weight loss medications: Orlistat, phentermine‑topiramate, naltrexone‑bupropion – support lifestyle interventions.

Type 1 diabetes / insulin‑deficient states:

· Insulin replacement: Essential. Regimens individualised (basal‑bolus, insulin pumps, premixed). No oral agents are effective in absolute insulin deficiency.

Insulinoma:

· Surgical resection: Curative in localised disease.

· Medical therapy (inoperable/metastatic):

· Diazoxide – opens potassium channels, inhibits insulin secretion; first‑line medical agent.

· Everolimus (mTOR inhibitor) – for metastatic neuroendocrine tumours.

· Somatostatin analogues (octreotide, lanreotide) – effective in somatostatin receptor‑positive tumours.

Postprandial (reactive) hypoglycaemia:

· Dietary modification: small, frequent, low‑glycaemic index meals; avoid simple sugars.

· Acarbose (alpha‑glucosidase inhibitor) – delays carbohydrate absorption, blunts postprandial insulin surge.

Do not self‑prescribe any of these medications. Insulin therapy carries risk of hypoglycaemia; metformin requires monitoring of renal function; sulfonylureas carry hypoglycaemia risk. All require specialist supervision.

b. Using Supplements or Holistic medicine

No supplement directly cures insulin resistance or replaces insulin. The following support insulin sensitivity, beta cell function, and metabolic health. They are adjuncts to, not substitutes for, medical therapy. Always inform your physician before initiating any supplement.

· Berberine:

· Rationale: Plant alkaloid from Berberis species; activates AMP‑kinase, improving insulin sensitivity and reducing hepatic gluconeogenesis. Multiple trials show HbA1c and fasting glucose reductions comparable to metformin.

· Effect on insulin: Reduces fasting hyperinsulinaemia in insulin‑resistant states.

· Dose: 500 mg twice daily with meals.

· Form: Standardised to 97–98% berberine. Avoid products blended with synthetic folic acid or cyanocobalamin.

· Caution: May cause constipation, flatulence. Avoid during pregnancy and breastfeeding. Potential drug interactions (cyclosporine, tacrolimus – increases levels).

· Omega‑3 fatty acids (EPA/DHA):

· Rationale: Anti‑inflammatory; improve insulin sensitivity in some studies. Reduce triglyceride levels and cardiovascular risk.

· Preferred source: Algae oil – exclusively plant‑based, sustainable, free from ocean pollutants. Choose re‑esterified triglyceride form with documented EPA+DHA content.

· Dose: 2–3 g combined EPA+DHA daily.

· Avoid: Conventional fish oil (overfishing, ecological harm, mercury, PCBs). Plant‑based ALA sources (flax, chia, hemp) do not provide sufficient EPA/DHA at practical intakes.

· Vitamin D3:

· Rationale: Deficiency is highly prevalent in insulin resistance and correlates with beta cell dysfunction. Supplementation may improve insulin sensitivity.

· Source: Lichen‑derived cholecalciferol (D3) – plant‑based, sustainable. Avoid D2 (ergocalciferol).

· Dose: 2000–4000 IU daily; adjust based on serum 25(OH)D (target 40–60 ng/mL).

· Magnesium:

· Rationale: Hypomagnesaemia is common in type 2 diabetes and impairs insulin signalling. Supplementation improves insulin sensitivity.

· Form: Magnesium glycinate, citrate, or malate. Avoid magnesium oxide (poor absorption).

· Dose: 300–400 mg elemental magnesium daily.

· Chromium picolinate:

· Rationale: Enhances insulin action. Evidence for HbA1c reduction modest; may benefit chromium‑deficient individuals.

· Dose: 200–1000 mcg daily (as chromium picolinate). Do not exceed 1000 mcg/day.

· Zinc:

· Rationale: Important for insulin synthesis, storage, and secretion. Deficiency impairs glucose tolerance.

· Form: Zinc picolinate, zinc acetate, or zinc citrate. Avoid zinc oxide.

· Dose: 20–40 mg elemental zinc daily.

· Alpha‑lipoic acid (ALA):

· Rationale: Potent antioxidant; improves insulin sensitivity and reduces oxidative stress. Used in diabetic neuropathy.

· Dose: 600 mg daily (R‑lipoic acid isomer has better bioavailability).

· Source: Fermentation‑derived, plant‑based.

· Probiotics:

· Rationale: Gut dysbiosis contributes to insulin resistance. Modulation of microbiota may improve metabolic parameters.

· Source: Non‑dairy, plant‑based fermentation cultures. Multi‑strain formulations containing Lactobacillus rhamnosus GG, Bifidobacterium lactis, Saccharomyces boulardii.

· Avoid products with synthetic folic acid or cyanocobalamin fillers.

· Herbs and Phytochemicals from Indian subcontinent:

· Gymnema sylvestre (Gurmar):

· Rationale: Ayurvedic herb ("sugar destroyer"). Gymnemic acids bind to taste receptors, reducing sugar craving, and may promote beta cell regeneration in animal studies. Human trials show modest HbA1c reduction.

· Form: Standardised extract (25% gymnemic acids).

· Dose: 400–600 mg daily before meals.

· Caution: May potentiate hypoglycaemia if used with insulin/sulfonylureas.

· Fenugreek (Trigonella foenum‑graecum):

· Rationale: Seeds rich in soluble fibre (galactomannan) delay carbohydrate absorption and improve glycaemic control.

· Form: Soaked seeds, powdered seeds, or standardised extract (4‑hydroxyisoleucine).

· Dose: 5–10 g powdered seeds daily with meals; or extract 500–1000 mg daily.

· Note: May cause mild gastrointestinal discomfort, flatulence.

· Turmeric (Curcuma longa):

· Rationale: Curcumin improves insulin sensitivity and reduces inflammation.

· Form: Phytosome, liposomal, or with piperine/fenugreek fibre (bioavailability‑enhanced).

· Dose: 500–1000 mg bioavailable curcumin daily.

· Caution: May interact with anticoagulants and immunosuppressants.

· Cinnamon (Cinnamomum verum):

· Rationale: Some studies show modest fasting glucose reduction; may involve insulin receptor activation. Evidence mixed.

· Form: Standardised extract (type A polymers); avoid cassia cinnamon in high doses (coumarin hepatotoxicity).

· Dose: 1–2 g daily or 250–500 mg extract.

· Vijayasar (Pterocarpus marsupium):

· Rationale: Traditional Ayurvedic remedy for diabetes. Contains pterostilbene; animal studies suggest beta cell regenerative potential. Human evidence limited.

· Form: Heartwood extract; traditionally water stored overnight in wooden glass.

· Caution: Insufficient human safety data; use only under expert guidance.

· Karela (Momordica charantia, bitter gourd):

· Rationale: Contains charantin, polypeptide‑p, and vicine; multiple mechanisms including insulin‑like action and enhanced glucose uptake.

· Form: Fresh juice, powdered extract, or capsules.

· Dose: 50–100 mL fresh juice daily; or 500–1000 mg extract.

· Caution: May cause hypoglycaemia, abdominal pain, diarrhoea.

· Amla (Emblica officinalis, Indian gooseberry):

· Rationale: Potent antioxidant, rich in vitamin C and tannins. Improves endothelial function and reduces oxidative stress in diabetes.

· Form: Fresh fruit, juice, or standardised extract.

· Dose: 1–2 g powder daily; 500 mg extract.

· Tulsi (Ocimum sanctum, holy basil):

· Rationale: Adaptogen; reduces cortisol and oxidative stress. Some evidence for modest glucose‑lowering effect.

· Form: Leaf extract or tea.

· Dose: 300–600 mg extract daily; 2–3 cups tea.

· Important cautions:

· Do not use supplements as monotherapy for diabetes. They are adjunctive only.

· Avoid proprietary "diabetes support" blends containing synthetic folic acid, cyanocobalamin, or undeclared pharmaceuticals.

· Herb‑drug interactions: Gymnema, fenugreek, bitter gourd, and cinnamon can potentiate hypoglycaemia when combined with insulin or sulfonylureas. Monitor blood glucose closely.

· Always inform your endocrinologist or diabetologist about all supplements.

c. Using Diet and Foods (Following a plant‑forward, ecologically sustainable, insulin‑sensitising approach)

Core dietary principles for metabolic health:

The dietary pattern that most effectively improves insulin sensitivity, preserves beta cell function, and lowers cardiovascular risk is a whole‑food, plant‑forward, low‑glycaemic index, high‑fibre diet. This pattern aligns perfectly with ecological sustainability.

Fundamental pattern:

· Mediterranean‑style, plant‑dominant diet: Abundant non‑starchy vegetables, legumes, whole grains, fruits, nuts, seeds, extra virgin olive oil.

· Low glycaemic load: Emphasise lentils, chickpeas, beans, barley, oats, quinoa, sweet potatoes (in moderation).

· High dietary fibre: ≥40 g daily. Soluble fibre (beta‑glucans, psyllium, pectin) delays glucose absorption and reduces postprandial insulin demand.

· Low in ultra‑processed foods, refined carbohydrates, added sugars, and industrial seed oils.

· Adequate but not excessive protein: Emphasise plant proteins (lentils, chickpeas, beans, tofu, tempeh).

Key dietary components:

· Legumes: Moong dal, masoor dal, chana dal, chickpeas, black beans, kidney beans, soybeans. Daily consumption improves glycaemic control and reduces fasting insulin in hyperinsulinaemic states.

· Whole grains: Brown rice, millets (ragi, jowar, bajra), oats, barley, quinoa. Millets have lower glycaemic index than rice/wheat.

· Vegetables: All non‑starchy vegetables, especially leafy greens, bitter gourd (karela), fenugreek leaves (methi), pumpkin, gourds.

· Fruits: Berries, apples, pears, guava, citrus – low glycaemic index. Avoid excessive tropical fruits (mango, banana, chikoo) in uncontrolled diabetes.

· Nuts and seeds: Almonds, walnuts, flaxseeds, chia seeds, hemp seeds. Ground flaxseed (1–2 tbsp daily) improves insulin sensitivity.

· Healthy fats: Extra virgin olive oil, avocado, cold‑pressed sesame or mustard oil (in moderation).

· Spices and herbs: Turmeric, fenugreek, cinnamon, curry leaves, ginger – incorporate daily in cooking.

Fungi:

· Medicinal mushrooms: Reishi (Ganoderma lucidum), maitake (Grifola frondosa), shiitake (Lentinula edodes) – contain beta‑glucans with immunomodulatory and potential insulin‑sensitising effects.

· Mycoprotein (Fusarium venenatum): Fermentation‑derived, high‑protein, low‑glycaemic meat alternative.

Fermented plant foods:

· Kimchi, sauerkraut, kombucha, tempeh, miso – support microbiome diversity, may improve insulin sensitivity.

Dairy and eggs:

· Permitted but not emphasised. Fermented dairy (yoghurt, kefir) preferable to milk. Some studies suggest low‑fat dairy is neutral or beneficial for type 2 diabetes risk. Eggs are acceptable; if consumed, choose omega‑3 enriched from pasture‑raised hens.

Foods to minimise or avoid:

· Red and processed meat: Associated with increased type 2 diabetes risk; pro‑inflammatory, high saturated fat, ecologically destructive.

· Industrial seed oils (soybean, corn, cottonseed): High omega‑6, pro‑inflammatory when consumed in excess.

· Trans fats: Avoid completely.

· Refined grains: White rice, white flour, maida, polished rice – rapidly absorbed, high glycaemic load.

· Sugary beverages: Single strongest dietary correlate of insulin resistance.

· Ultra‑processed plant‑based meats: Often high in saturated fat, sodium, and additives; not recommended.

Special consideration for type 1 diabetes:

· Carbohydrate counting with insulin adjustment is essential; no specific dietary pattern is universally superior, but plant‑based patterns are safe and effective when appropriately planned.

· Fibre‑rich, low‑glycaemic index meals reduce postprandial glucose excursions.

· Avoid hypoglycaemia: Consistent carbohydrate intake, regular meals.

---

6. How soon can one expect improvement and the ideal time frame to retest

Insulin is not a routine monitoring test. It is used for initial diagnosis and occasionally to reassess beta cell function. The following timelines apply to underlying conditions:

Insulin resistance / type 2 diabetes (early):

· Lifestyle intervention: Weight loss of 5–10% improves insulin sensitivity; fasting insulin may decline over 3–6 months.

· Metformin: Fasting insulin may decrease after several months as insulin sensitivity improves.

· GLP‑1 agonists / SGLT2 inhibitors: Glycaemic improvement within weeks; long‑term benefit on beta cell preservation may be reflected in stable or slower rise of insulin resistance indices over years.

Type 1 diabetes:

· Partial remission ("honeymoon") phase: Insulin requirements may decrease; residual beta cell function can be assessed by stimulated C‑peptide, not insulin.

Insulinoma:

· Post‑resection: Insulin normalises within hours; confirm with fasting glucose.

Retesting indications:

· Initial diagnosis of diabetes: Fasting insulin with glucose for HOMA‑IR if phenotyping ambiguous.

· Evaluation of hypoglycaemia: During spontaneous or provoked episode.

· Research or specialised clinical settings (e.g., PCOS, metabolic syndrome).

· Not indicated for routine monitoring of glycaemic control in established diabetes.

Retesting interval:

· For HOMA‑IR: Reassess after 3–6 months of lifestyle/pharmacologic intervention if clinically indicated.

· For hypoglycaemia evaluation: Test during symptoms; repeat if necessary to capture episode.

---

Conclusion

Insulin is the central actor in the drama of glucose metabolism – the hormone that opens cellular doors to fuel, that stores energy for times of need, and whose dysfunction underpins some of the most prevalent chronic diseases of our era. Yet the blood insulin level itself is a supporting character, not the lead. We measure it to distinguish the whisper of autoimmune destruction from the roar of resistance, to unmask the surreptitious insulinoma, to quantify the metabolic mayhem of the syndrome that bears its name. Treatment is never directed at the insulin number; it is directed at restoring balance – through metformin and lifestyle for the resistant, through insulin itself for the deficient, through surgery for the autonomous. Along this path, we are privileged to offer adjuncts from nature: berberine that mimics ancient molecules, gymnema that dulls the craving for sweetness, fenugreek that slows the rush of glucose. And we do so with reverence for the planet, choosing algae oil over fish oil, lentils over red meat, and the wisdom of millennia over the haste of commerce. Insulin is a measure of function, not a measure of worth. Treat the person, interpret the number, and always pair it with glucose – its inseparable partner.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations. In metabolic health and diabetes, this hierarchy aligns with evidence‑based dietary patterns for insulin sensitivity and cardiovascular risk reduction.

-x-x